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 2 
Summary 52 
The inflammatory bowel diseases (IBD) are chronic gastrointestinal inflammatory 53 
disorders that affect millions worldwide. Genome-wide association studies have 54 
identified 200 IBD-associated loci, but few have been conclusively resolved to specific 55 
functional variants. Here we report fine-mapping of 94 IBD loci using high-density 56 
genotyping in 67,852 individuals. We pinpointed 18 associations to a single causal 57 
variant with >95% certainty, and an additional 27 associations to a single variant with 58 
>50% certainty.  These 45 variants are significantly enriched for protein-coding changes 59 
(n=13), direct disruption of transcription factor binding sites (n=3) and tissue specific 60 
epigenetic marks (n=10), with the latter category showing enrichment in specific immune 61 
cells among associations stronger in CD and in gut mucosa among associations stronger 62 
in UC.  The results of this study suggest that high-resolution fine-mapping in large 63 
samples can convert many GWAS discoveries into statistically convincing causal 64 
variants, providing a powerful substrate for experimental elucidation of disease 65 
mechanisms.   66 
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The inflammatory bowel diseases (IBD) are a group of chronic, debilitating disorders of 67 
the gastrointestinal tract with peak onset in adolescence and early adulthood. More than 68 
1.4 million people are affected in the USA alone1, with an estimated direct healthcare 69 
cost of $6.3 billion/year. IBD affects millions worldwide, and is rising in prevalence, 70 
particularly in pediatric and non-European ancestry populations2. IBD has two subtypes, 71 
ulcerative colitis (UC) and Crohn’s disease (CD), which have distinct presentations and 72 
treatment courses. To date, 200 genomic loci have been associated with IBD3,4, but only a 73 
handful have been conclusively ascribed to a specific causal variant with direct insight 74 
into the underlying disease biology. This scenario is common to all genetically complex 75 
diseases, where the pace of identifying associated loci outstrips that of defining specific 76 
molecular mechanisms and extracting biological insight from each association.  77 
The widespread correlation structure of the human genome (known as linkage 78 
disequilibrium, or LD) often results in similar evidence for association among many 79 
neighboring variants.  However, unless LD is perfect (r2 = 1), it is possible, with a 80 
sufficiently large sample size, to statistically resolve causal variants from neighbors even 81 
at high levels of correlation (Extended Data Figure 1 and ref 5).  Novel statistical 82 
approaches applied to very large datasets that address this problem6 require that the 83 
highly correlated variants are directly genotyped or imputed with certainty.  Truly high-84 
resolution mapping data, when combined with increasingly sophisticated and 85 
comprehensive public databases annotating the putative regulatory function of DNA 86 
variants, are likely to reveal novel insights into disease pathogenesis7-9 and the 87 
mechanisms of disease-associated variants. 88 
Genetic architecture of associated loci 89 
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We genotyped 67,852 individuals of European ancestry, including 33,595 IBD (18,967 90 
CD and 14,628 UC) and 34,257 healthy controls using the Illumina™ Immunochip 91 
(Extended Data Table 1). This genotyping array was designed to include all known 92 
variants from European individuals in the February 2010 release of the 1000 Genomes 93 
Project10,11 in 187 high-density regions known to be associated to one or more immune-94 
mediated diseases12. Because fine-mapping uses subtle differences in strength of 95 
association between tightly correlated variants to infer which is most likely to be causal, 96 
it is particularly sensitive to data quality. We therefore performed stringent quality 97 
control to remove genotyping errors and batch effects (Methods). We imputed into this 98 
dataset from the 1000 Genomes reference panel13,14 to fill in variants missing from the 99 
Immunochip, or filtered out by our quality control (Extended Data Figure 2). We then 100 
evaluated the 97 high-density regions that had previous IBD associations3 and contained 101 
at least one variant that showed significant association (Methods) in this data set. The 102 
major histocompatibility complex was excluded from these analyses as fine-mapping has 103 
been reported elsewhere15.  104 
We applied three complementary Bayesian fine-mapping methods that used 105 
different priors and model selection strategies to identify independent association signals 106 
within a region, and to assign a posterior probability of causality to each variant 107 
(Supplementary Methods and Extended Data Figure 2). For each independent signal 108 
detected by each method, we sorted all variants by the posterior probability of 109 
association, and added variants to the ‘credible set’ of associated variants until the sum of 110 
their posterior probability exceeded 95%   – that is, the credible set contains the minimum 111 
list of DNA variants that are >95% likely to contain the causal variant (Figure 1). These 112 
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sets ranged in size from one to > 400 variants.  We merged these results  and 113 
subsequently focused only on signals where an overlapping credible set of variants was 114 
identified by at least two of the three methods and all variants were either directly 115 
genotyped or imputed with INFO score > 0.4 (Methods and Figure 1).  116 
In three out of 97 regions, a consistent credible set could not be identified; when 117 
multiple independent effects exist in a region of very high LD, multiple distinct fine-118 
mapping solutions may not be distinguishable (Supplementary Note).  Sixty-eight of the 119 
remaining 94 regions contain a single association, while 26 harbor two or more 120 
independent signals, for a total of 139 independent associations defined across the 94 121 
regions (Figure 2a).  Only IL23R and NOD2 (both previously established to contain 122 
multiple associated protein-coding variants16) contain more than three independent 123 
signals.  Consistent with previous reports3, the vast majority of signals are associated 124 
with both CD and UC, though many of these have a significantly stronger association 125 
with one subtype.  For the purposes of enrichment analyses below, we compared 79 126 
signals that are more strongly associated with CD to 23 signals that are more strongly 127 
associated with UC (the remaining 37 were equally associated with both subtypes, 128 
Supplementary Table 1).  129 
Using a restricted maximum likelihood mixed model approach17, we evaluated the 130 
proportion of total variance in disease risk attributed to these 94 regions and how much of 131 
that is explained by the 139 specific associations. We estimated that 25% of CD risk was 132 
explained by the specific associations described here, out of a total of 28% explained by 133 
these loci (correspondingly for UC: 17% out of 22%). The single strongest signals in 134 
each region contribute 76% of this variance explained and the remaining associations 135 
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contribute 24% (Extended Data Figure 3), highlighting the importance of secondary and 136 
tertiary associations in GWAS results15,18. 137 
Associations mapped to a single variant 138 
For 18 signals, the 95% credible set consisted of a single variant (‘single variant credible 139 
sets’), and for 24 others the credible set consisted of two to five variants (Figure 2b).  The 140 
single variant credible sets included five previously reported coding variants: three in 141 
NOD2 (fs1007insC, R702W, G908R), a rare protective allele in IL23R (V362I) and a 142 
splice variant in CARD9 (c.IVS11+1G>C) 16,19. The remaining single variant credible sets 143 
were comprised of three missense variants (I170V in SMAD3, I923V in IFIH1 and 144 
N289S in NOD2), four intronic variants (in IL2RA, LRRK2, NOD2 and 145 
RTEL1/TNFRSF6B) and six intergenic variants (located 3.7kb downstream of GPR35; 146 
3.9kb upstream of PRDM1; within a EP300 binding site 39.9 kb upstream of IKZF1; 500 147 
bp before the transcription start site of JAK2; 9.4kb upstream of NKX2-3; and 3.5kb 148 
downstream from HNF4A) (Table 1). Of note, while physical proximity does not 149 
guarantee functional relevance, the credible set of variants for 30 associated loci now 150 
implicates a specific gene either because it resides within 50 kb of only that gene or has a 151 
coding variant with >50% probability – improved from only 3 so refined using an earlier 152 
HapMap-based definition.  Using the same definitions, the total number of potential 153 
candidate genes was reduced from 669 to 233.  Examples of IBD candidate genes clearly 154 
prioritized in our data are described in the Supplementary Box, and a customizable 155 
browser (http://finemapping.broadinstitute.org/) is available to review the detailed fine-156 
mapping results. 157 
 158 
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Associated protein coding variants 159 
We first annotated the possible functional consequences of the IBD variants by their 160 
effect on the amino acid sequences of proteins. Thirteen out of 45 variants (Figure 2c) 161 
that have >50% posterior probability are non-synonymous (Table 1), an 18-fold 162 
enrichment (enrichment P=2x10-13, Fisher’s exact test) relative to randomly drawn 163 
variants in our regions (Figure 3a).  By contrast, only one variant with >50% probability 164 
is synonymous (enrichment P=0.42).  All common coding variants previously reported to 165 
affect IBD risk are included in a 95% credible set including: IL23R (R381Q, V362I and 166 
G149R); CARD9 (c.IVS11+1G>C and S12N); NOD2 (S431L, R702W, V793M, N852S 167 
and G908R, fs1007insC); ATG16L1 (T300A);  PTPN22 (R620W); and FUT2 (W154X). 168 
While this enrichment of coding variation (Figure 3a) provides assurance about the 169 
accuracy of our approach, it does not suggest that 30% of all associations are caused by 170 
coding variants; rather, it is almost certainly the case that associated coding variants have 171 
stronger effect sizes, making them easier to fine-map. 172 
 173 
Associated non-coding variants  174 
We next examined conserved nucleotides in high confidence binding site motifs of 84 175 
transcription factor (TF) families20 (Methods). There was a significant positive 176 
correlation between TF motif disruption and IBD association posterior probability 177 
(P=0.006, logistic regression) (Figure 3a), including three variants with >50% probability 178 
(two >95%).  In the RTEL1/TNFRSF6B region, rs6062496 is predicted to disrupt a TF 179 
binding site (TFBS) for EBF1, a TF involved in the maintenance of B cell identity and 180 
prevention of alternative fates in committed cells21.  A low frequency (3.6%) protective 181 
 8 
allele at rs74465132 creates a binding site for EP300 less than 40kbp upstream of IKZF1. 182 
The third notable example of TFBS disruption, although not in a single variant credible 183 
set, is detailed in the Supplementary Box for the association at SMAD3. 184 
Recent studies have shown that trait associated variants are enriched for 185 
epigenetic marks highlighting cell type specific regulatory regions9,22,23. We compared 186 
our credible sets with ChIPseq peaks corresponding to chromatin immunoprecipitation 187 
with H3K4me1, H3K4me3 and H3K27ac (shown previously22,23 to highlight enhancers, 188 
promoters and active regulatory elements, respectively) in 120 adult and fetal tissues, 189 
assayed by the Roadmap Epigenomics Mapping Consortium24 (Figure 3b). Using a 190 
threshold of P=1.3x10-4 (0.05 corrected for 360 tests), we observed significant 191 
enrichment of H3K4me1 in 6 immune cell types and for H3K27ac in 2 gastrointestinal 192 
(gut) samples (sigmoid colon and rectal mucosa) (Figure 3b and Supplementary Table 2).  193 
The subset of signals that are more strongly associated with CD overlap more with 194 
immune cell chromatin peaks, whereas UC signals overlap more with gut chromatin 195 
peaks (Supplementary Table 2). 196 
These three chromatin marks are correlated both within tissues (we observe 197 
additional signal in other marks in the tissues described above) and across related tissues.  198 
We therefore defined a set of “core immune peaks” for H3K4me1 and “core gut peaks” 199 
for H3K27ac as the set of overlapping peaks in all enriched immune cell and gut tissue 200 
types, respectively.  These two sets of peaks are independently significant and capture the 201 
observed enrichment compared to “control peaks” made up of the same number of 202 
ChIPseq peaks across our 94 regions in non-immune and non-gut tissues (Figure 3c,d).  203 
These two tracks summarize our epigenetic-GWAS overlap signal, and the combined 204 
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excess over the baseline suggests that a substantial number of regions, particularly those 205 
not mapped to coding variants, may ultimately be explained by functional variation in 206 
recognizable enhancer/promoter elements. 207 
 208 
Overlap with expression QTLs 209 
Variants that change enhancer or promoter activity might change gene expression, and 210 
baseline expression of many genes has been found to be regulated by genetic variation25-211 
27.  Indeed, it has been suggested that these so-called expression quantitative trait loci 212 
(eQTLs) underlie a large proportion of GWAS associations25,28.  We therefore searched 213 
for variants that are both in an IBD-associated credible set with 50 or fewer variants, and 214 
the most significantly associated eQTL variant for a gene in a study29 of peripheral blood 215 
mononuclear cells (PBMC) from 2,752 twins.  Sixty-eight of the 76 regions with signals 216 
fine-mapped to ≤ 50 variants harbor at least one significant eQTL (affecting a gene 217 
within 1 Mb with P < 10-5).  Despite this abundance of eQTLs in fine-mapped regions, 218 
only 3 credible sets include the most significantly associated eQTL variants, compared 219 
with 3.7 expected by chance (Methods).  Data from a more recent study30 using PBMCs 220 
from 8,086 individuals did not yield a substantively different outcome, demonstrating a 221 
modest but non-significant enrichment (8 observed overlaps, 4.2 expected by chance, 222 
P=0.06).  Using a more lenient definition of overlap which requires the lead eQTL 223 
variant to be in LD (R2 > 0.4) with an IBD credible set variant increased the number of 224 
potential overlaps but again these numbers were not greater than chance expectation.  225 
As PBMCs are a heterogeneous collection of immune cell populations, cell type-226 
specific signals or signals corresponding to genes expressed most prominently in non-227 
 10 
immune tissues may be missed.  We therefore tested the enrichment of eQTLs that 228 
overlap credible sets in five primary immune cell populations (CD4+, CD8+, CD19+, 229 
CD14+ and CD15+), platelets, and three distinct intestinal locations (rectum, colon and 230 
ileum) isolated from 350 healthy individuals (Methods). We observed a significant 231 
enrichment of credible SNP/eQTL overlaps in CD4+ cells and ileum (Extended Data 232 
Table 2): three and two credible sets overlapped eQTLs, respectively, compared to 0.4 233 
and 0.3 expected by chance (P=0.005 and 0.020).  An enrichment was also observed for 234 
the naïve CD14+ cells from another study31: eight overlaps observed compared to 2.7 235 
expected by chance (P=0.001).  We did not observe enrichment of overlaps in stimulated 236 
(with interferon or lipopolysaccharide) CD14+ cells from the same source (Extended 237 
Data Table 2).  238 
We investigated eQTL overlaps more deeply by applying two colocalization 239 
approaches (one frequentist, one Bayesian, Methods) to the our cell-separated dataset 240 
where primary genotype and expression data were available. We confirmed greater than 241 
expected overlap with eQTLs in CD4+ and ileum described above (Figure 4 and 242 
Extended Data Table 2). These CD4+ colocalized eQTLs also had stronger overlap with 243 
CD4+ ChIPseq peaks than our other credible sets, further supporting a regulatory causal 244 
mechanism. The number of colocalizations in other purified cell types and tissues was 245 
largely indistinguishable from what we expect under the null using either method, except 246 
for moderate enrichment in rectum (4 observed and 1.4 expected, P=0.039, Frequentist 247 
approach) and colon (3 observed and 0.8 expected, P=0.04, Bayesian approach).  Only 248 
two of these colocalizations correspond to an IBD variant with causal probability > 50% 249 
(Table 1 and Extended Data Figure 4a).  250 
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 251 
Discussion 252 
We have performed fine-mapping of 94 previously reported genetic risk loci for IBD.  253 
Rigorous quality control followed by an integration of three novel fine-mapping methods 254 
generated lists of genetic variants accounting for 139 independent associations across 255 
these loci. Our methods are concordant with an existing fine-mapping method6 (67 of 68 256 
credible sets in single signal regions overlap, including exact matches for all single 257 
variant credible sets), and provide extensions to support the phenotype assignment (CD, 258 
UC or IBD) and the conditional estimation of multiple credible sets in loci with multiple 259 
independent signals. The use of multiple methods allowed us to focus our downstream 260 
analyses on loci where the choice of fine-mapping method did not substantially alter 261 
conclusions about the biology of IBD. Our results improve on previous fine-mapping 262 
efforts using a preset LD threshold32 (e.g. r2> 0.6) (Extended Data Figure 5) by formally 263 
modeling the posterior probability of association of every variant.  Much of this 264 
resolution derives from the very large sample size we employed, because the number of 265 
variants in a credible set decreases with increasing significance (P=0.0069).   266 
The high-density of genotyping also aids in improved resolution.  For instance, 267 
the primary association at IL2RA has now been mapped to a single variant associated 268 
with CD, rs61839660.  This variant was not present in the Hapmap 3 reference panel and 269 
was therefore not reported in earlier studies3,33 (nearby tagging variants, rs12722489 and 270 
rs12722515, were reported instead).  Imputation using the 1000 genomes reference panel 271 
and the largest assembled GWAS dataset3 did not separate rs61839660 from its neighbors 272 
(unpublished results), due to the loss of information in imputation using the limited 273 
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reference.  Only direct genotyping, available in the immunochip high-density regions, 274 
permitted the conclusive identification of the causal variant.  275 
Accurate fine-mapping should, in many instances, ultimately point to the same 276 
variant across diseases in shared loci.  Among our single-variant credible sets, we fine-277 
mapped a UC association to a rare missense variant (I923V) in IFIH1, which is also 278 
associated with type 1 diabetes (T1D)37  with an opposite direction of effect 279 
(Supplementary Box). The intronic variant noted above (rs61839660, AF=9%) in IL2RA 280 
was also similarly associated with T1D, again with a discordant directional effect38 281 
(Supplementary Box). Simultaneous high-resolution fine-mapping in multiple diseases 282 
should therefore better clarify both shared and distinct biology. 283 
Resolution of fine-mapping can be further improved by leveraging LD from other 284 
ethnicities34.  However, the sample size from other ethnicities we have collected is small 285 
compared with European samples (9,846 across East-Asian, South-Asian and Middle-286 
Eastern). Limited access to matched imputation reference panels from all cohorts and the 287 
fact that the smaller non-European sets are not from populations (e.g., African-derived) 288 
with narrower LD also suggest that gains in fine-mapping accuracy would be limited at 289 
this time. Ultimately this effort will be aided by more substantial investment in 290 
genotyping non-European population samples and by developing and applying more 291 
robust trans-ethnic fine-mapping algorithms. 292 
A new release of the 1000 genomes (phase 3)35  and the UK10K36 project have 293 
introduced new variants that were not present in the reference panel in our study.  Our 294 
major findings remain the same using this new reference panel: the 18 single-variant 295 
credible sets are not in high LD (r2 > 0.95) with any new variants in either new dataset, 296 
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and the 1,426 variants in IBD associations mapped to ≤50 variants are in high LD with 297 
only 47 new variants (3.3% of the total size of these credible sets, Supplementary Table 298 
1). Given that this release represents a near complete catalogue of variants with minor 299 
allele frequency (MAF) > 1% in European populations, we believe our current fine 300 
mapping results are likely to be robust, especially for common variant associations. High-301 
resolution fine-mapping demonstrates that causal variants are significantly enriched for 302 
variants that alter protein coding variants or disrupt transcription factor binding motifs.  303 
Enrichment was also observed in H3K4me1 marks in immune related cell types and 304 
H3K27ac marks in sigmoid colon and rectal mucosal tissues, with CD loci demonstrating 305 
a stronger immune signature and UC loci more enriched for gut tissues (P values are 306 
0.014, 0.0005 and 0.0013 respectively for H3K4me1, H3K27ac and H3K4me3; chi-307 
square test).  By contrast, overall enrichment of eQTLs is quite modest compared with 308 
prior reports and not seen strongly in excess of chance in our well-refined credible sets (≤ 309 
50 variants).  This result underscores the importance of high-resolution mapping and the 310 
careful incorporation of the high background rate of eQTLs.  It is worth noting that 311 
evaluating the overlap between two distinct mapping results is fundamentally different 312 
than comparing genetic mapping results to fixed genomic features, and depends on both 313 
mappings being well resolved.  While these data challenge the paradigm that easily 314 
surveyed baseline eQTLs explain a large proportion of non-coding GWAS signals, the 315 
modest excesses observed in smaller but cell-specific data sets suggest that much larger 316 
tissue or cell-specific studies (and under the correct stimuli or developmental time points) 317 
will resolve the contribution of eQTLs to GWAS hits.  318 
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Resolving multiple independent associations may often help target the causal gene 319 
more precisely. For example, the SMAD3 locus hosts a non-synonymous variant and a 320 
variant disrupting the conserved transcription factor binding site (also overlapping the 321 
H3K27ac marker in gut tissues), unambiguously articulating a role in disease and 322 
providing an allelic series for further experimental inquiry.  Similarly, the TYK2 locus has 323 
been mapped to a non-synonymous variant and a variant disrupting a conserved 324 
transcription factor binding site (http://finemapping.broadinstitute.org/).   325 
One-hundred and sixteen associations have been fine-mapped to ≤ 50 variants.  326 
Among them, 27 associations contain coding variants, 20 contain variants disrupting 327 
transcription factor binding motifs, and 45 are within histone H3K4me1 or H3K27ac 328 
marked DNA regions. The best-resolved associations - 45 variants having >50% posterior 329 
probabilities for being causal (Table 1) – are similarly significantly enriched for variants 330 
with known or presumed function from genome annotation. Of these, 13 variants cause 331 
non-synonymous change in amino acids, three disrupt a conserved TF binding motif, ten 332 
are within histone H3K4me1 or H3K27ac marked DNA regions in disease-relevant 333 
tissues, and two colocalize with a significant cis-eQTL (Extended Data Figure 4a). Risk 334 
alleles of these variants can be found throughout the allele frequency spectrum, with 335 
protein coding variants having somewhat larger effects and more extreme risk allele 336 
frequencies (Extended Data Figure 6a-c).  337 
This analysis, however, leaves 21 non-coding variants (Extended Data Figure 4b), 338 
all of which have >50% probabilities to be causal (five have >95%), that are not located 339 
within known motifs, annotated elements, nor in any experimentally determined ChIPseq 340 
peaks or eQTL credible sets yet discovered.  While we have identified a statistically 341 
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compelling set of genuine associations (often intronic or within 10 kb of strong candidate 342 
genes), we can make little inference about function.  For example, the intronic single-343 
variant credible set of LRRK2 has no annotation, eQTL or ChIPseq peak of note.  This 344 
underscores the incompleteness of our knowledge regarding the function of non-coding 345 
DNA and its role in disease, and calls for comprehensive studies on transcriptome and 346 
epigenome in a wide range of cell lines and stimulation conditions.  That the majority of 347 
the best-refined non-coding associations have no available annotation is perhaps sobering 348 
with respect to how well we may currently be able to interpret non-coding variation in 349 
medical sequencing efforts.  It does suggest, however, that detailed fine-mapping of 350 
GWAS signals down to single variants, combined with emerging high-throughput 351 
genome-editing methodology, may be among the most effective ways to advance to a 352 
greater understanding of the biology of the non-coding genome.  353 
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Table 1. Variants having posterior probability >50%.  492 
Variant Chr Position Ns Phe AF Prob INFO Func Annotation 
Signals mapped to a single variant 
rs7307562 12 40724960 2 CD 0.398 0.999 1  LRRK2(intronic) 
rs2066844 16 50745926 10 CD 0.063 0.999 0.8 C NOD2(R702W) 
rs2066845 16 50756540 10 CD 0.022 0.999 1 C NOD2(G908R) 
rs6017342 20 43065028 2 UC 0.544 0.999 1 E HNF4A (downstream), 
Gut_H3K27ac 
rs61839660 10 6094697 2 CD 0.094 0.999 1 E IL2RA(intronic), 
Immune_H3K4me1 
rs5743293 16 50763781 10 CD 0.964 0.999 1 C NOD2(fs1007insC) 
rs6062496 20 62329099 1 IBD 0.587 0.996 1 T RTEL1-
TNFRSF6B(ncRNA_intronic),  
EBF1 TFBS 
rs141992399 9 139259592 3 IBD 0.005 0.995 1 C CARD9(1434+1G>C) 
rs35667974 2 163124637 1 UC 0.021 0.994 1 C IFIH1(I923V) 
rs74465132 7 50304782 3 IBD 0.034 0.994 1 T,E IKZF1(upstream),  
EP300 TFBS,  
Immune_H3K4me1 
rs4676408 2 241574401 1 UC 0.508 0.994 0.99  GPR35(downstream) 
rs5743271 16 50744688 10 CD 0.007 0.993 1 C NOD2(N289S) 
rs10748781 10 101283330 2 IBD 0.55 0.990 1 E NKX2-3 (upstream), 
Gut_H3K27ac 
rs35874463 15 67457698 2 IBD 0.054 0.989 1 C,E SMAD3(I170V),  
Gut_H3K27ac 
rs72796367 16 50762771 10 CD 0.023 0.983 1  NOD2(intronic) 
rs1887428 9 4984530 1 IBD 0.603 0.974 0.97  JAK2(upstream) 
rs41313262 1 67705900 5 CD 0.014 0.973 1 C IL23R(V362I) 
rs28701841 6 106530330 2 CD 0.116 0.971 1  PRDM1 (upstream) 
Signals mapped to 2-50 variants and the lead variant has posterior probability > 50%  
rs76418789 1 67648596 5 CD 0.006 0.937 0.59 C IL23R(G149R) 
rs7711427 5 40414886 3 CD 0.633 0.919 1   
rs1736137 21 16806695 2 CD 0.407 0.879 1   
rs104895444 16 50746199 10 CD 0.003 0.865 1 C NOD2(V793M) 
rs56167332 5 158827769 2 IBD 0.353 0.845 1  IL12B 
rs104895467 16 50750810 10 CD 0.002 0.833 1 C NOD2(N852S) 
rs630923 11 118754353 2 CD 0.153 0.820 0.98   
rs3812565 9 139272502 3 IBD 0.402 0.815 1 Q eQTL of INPP5E in CD4 and 
CD8; CARD9 in CD14  
rs4655215 1 20137714 3 UC 0.763 0.784 1 E Gut_H3K27ac 
rs145530718 19 10568883 3 CD 0.023 0.762 0.97   
rs6426833 1 20171860 3 UC 0.555 0.752 1   
chr20: 
43258079 
20 43258079 2 CD 0.041 0.736 0.88   
rs17229679 2 199560757 2 UC 0.028 0.716 1   
rs4728142 7 128573967 1 UC 0.448 0.664 1 E Immune_H3K4me1 
rs2143178 22 39660829 2 IBD 0.157 0.662 1 T,E NFKB TFBS, Gut_H3K27ac 
rs34536443 19 10463118 3 CD 0.038 0.649 1 C TYK2(P1104A) 
rs138425259 16 50663477 10 UC 0.009 0.648 0.92   
rs146029108 9 139329966 3 CD 0.036 0.643 0.92   
rs12722504 10 6089777 2 CD 0.26 0.615 1   
rs60542850 19 10488360 3 IBD 0.17 0.591 0.89   
rs2188962 5 131770805 1 CD 0.44 0.590 1 E,Q Gut_H3K27ac,  
eQTL of SLC22A5 in CD14, 
CD15 and IL 
rs2019262 1 67679990 5 IBD 0.4 0.586 1   
rs3024493 1 206943968 2 IBD 0.171 0.537 1 E Immune_H3K4me1 
rs7915475 10 64381668 3 CD 0.304 0.528 1   
rs77981966 2 43777964 1 CD 0.077 0.521 1   
rs9889296 17 32570547 1 CD 0.264 0.512 1   
rs2476601 1 114377568 1 CD 0.908 0.508 1 C PTPN22(W620R) 
Ns: number of independent signals in the locus. Phe: phenotype. AF: allele frequency. 493 
Prob: posterior probability for being a causal variant. INFO: imputation. Func: functional 494 
annotations --  coding (C), disrupting transcription factor binding sites (T), overlapping 495 
epigenetic peaks (E) and colocalization with eQTL (Q).  496 
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Figure 1. Fine-mapping procedure and output using the SMAD3 region as an 498 
example. a, 1) We merge overlapping signals across methods; 2) select a lead variant 499 
(black triangle) and phenotype (color); and 3) choose the best model. Details for each 500 
step are available in Methods. b, Example fine-mapping output. This region has been 501 
mapped to two independent signals. For each signal, we report the phenotype it is 502 
associated with (colored), the variants in the credible set, and their posterior probabilities. 503 
 504 
Figure 2. Summary of fine-mapped associations. a, Independent signals. Sixty-eight 505 
loci containing one association and 26 loci containing multiple associations. b, Number 506 
of variants in credible sets. 18 associations were fine-mapped to a single variant, and 116 507 
to ≤ 50 variants. c, Distribution of the posterior probability of the variants in credible sets 508 
having ≤ 50 variants. 509 
 510 
Figure 3. Functional annotation of causal variants.  a, Proportion of credible variants 511 
that are protein coding, disrupt/create transcription factor binding motif sites (TFBS) or 512 
are synonymous, sorted by posterior probability.  b, Epigenetic peaks overlapping 513 
credible variants in cell and tissue types from the Roadmap Epigenomics Consortium39.  514 
Significant enrichment has been marked with asterisks.	Proportion of credible variants 515 
that overlap (c) core immune peaks for H4K4me1or (d) core gut peaks for H3K27ac 516 
(Methods). In panels a, c and d, the vertical dotted lines mark 50% posterior probability 517 
and the horizontal dashed lines show the background proportions of each functional 518 
category. 519 
 520 
Figure 4. Number of credible sets that colocalize eQTLs.  Distributions of the number 521 
of colocalizations by chance (violins) and observed number of colocalizations with p-522 
values (dots). Both the background and the observed numbers were calculated using the 523 
“Frequentist colocalization using conditional P values” approach (Methods).   524 
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Methods 525 
Genotyping and QC 526 
We genotyped 35,197 unaffected and 35,346 affected individuals (20,155 CD and 15,191 527 
UC) using the Immunochip array. Genotypes were called using optiCall40 for 192,402 528 
autosomal variants before QC. We removed variants with missing data rate >2% across 529 
the whole dataset, or >10% in any one batch, and variants that failed (FDR < 10-5 in 530 
either the whole dataset or at least two batches) tests for: a) Hardy-Weinberg equilibrium 531 
in controls; b) differential missingness between cases and controls; c) different allele 532 
frequency across different batches in controls, CD or UC. We also removed non-coding 533 
variants that were present in the 1000 Genomes pilot stage but were not in the subsequent 534 
Phase I integrated variant set (March 2012 release) and had not been in releases 2 or 3 of 535 
HapMap as these mostly represent false positives from the 1000 Genomes pilot, which 536 
often genotype poorly. Where a variant failed in exactly one batch we set all genotypes to 537 
missing for that batch (to be reimputed later) and included the site if it passed in the 538 
remainder of the batches. We removed individuals that had >2% missing data, had 539 
significantly higher or lower (defined as FDR<0.01) inbreeding coefficient (F), or were 540 
duplicated or related (PI_HAT ≥ 0.4, calculated from the LD pruned dataset described 541 
below), by sequentially removing the individual with the largest number of related 542 
samples until no related samples remain. We projected all remaining samples onto 543 
principal component axes generated from HapMap 3, and classified their ancestry using a 544 
Gaussian mixture model fitted to the European (CEU+TSI), African 545 
(YRI+LWK+ASW+MKK), East Asian (CHB+JPT) and South Asian (GIH) HapMap 546 
samples. We removed all samples that were classified as non-European, or that lay more 547 
 22 
than 8 standard deviations from the European cluster.  After QC, there were 67,852 548 
European-derived samples with valid diagnosis (healthy control, CD or UC), and 161,681 549 
genotyped variants available for downstream analyses.  550 
Linkage-disequilibrium pruning and principal components analysis 551 
From the clean dataset we removed variants in long range LD41 or with MAF < 0.05, and 552 
then pruned 3 times using the ‘--indep’ option in PLINK (with window size of 50, step 553 
size of 5 and VIF threshold of 1.25). Principal component axes were generated within 554 
controls using this LD pruned dataset (18,123 variants). The axes were then projected to 555 
cases to generate the principal components for all samples.  The analysis was performed 556 
using our in-house C code (https://github.com/hailianghuang/efficientPCA) and 557 
LAPACK package42 for efficiency.  558 
Controlling for population structure, batch effects and other confounders 559 
We used 2,853 “background SNPs” present on the Immunochip but not known to be 560 
associated with immune disorders to calculate the genomic inflation factor λGC. After 561 
including the first five principal components calculated above as covariates, λGC = 1.29, 562 
1.25 and 1.31 for CD, UC and IBD (adding additional principal components did not 563 
further reduce λGC, Extended Data Table 3a). Because our genotype data were processed 564 
in 15 batches with variable ratios of cases to controls, we conducted two analyses to 565 
ensure possible batch effects were adequately controlled. First, we split the samples into a 566 
“balanced” cohort with studies that have both cases and controls and an “imbalanced” 567 
cohort with studies that have exclusively cases or controls (Extended Data Table 1). As 568 
λGC under polygenic inheritance scales with the sample size43, we randomly down-569 
sampled the full dataset to match the sample size of the balanced and the imbalanced 570 
 23 
cohorts respectively.  We tested for association in these subsets of our data (and included 571 
batch ID as a covariate in the balanced cohort), and found the λGC from the balanced and 572 
imbalanced cohorts to be within the 95% confidence interval of size matched values from 573 
our full data, suggesting that batch effects are not systematically inflating our association 574 
statistics (Extended Data Table 3b).  We also performed a heterogeneity test for the odds 575 
ratio (OR) of lead variants in each credible set using the balanced and imbalanced cohorts, 576 
and observed no significant heterogeneity after Bonferroni correction (Supplementary 577 
Table 3).  578 
We next sought to disentangle the contributions of polygenic inheritance and 579 
uncorrected population structure in our observed λGC. LD score regression44 is able to 580 
differentiate these two effects, but requires genome-wide data, so is not possible in our 581 
Immunochip dataset. Instead, we compared λGC and λ1000 values calculated using the 582 
same set of background SNPs from the largest IBD meta-analysis with genome-wide 583 
data45. For both CD and UC the λ1000 values in our Immunochip study (1.012 and 1.012) 584 
were equal or less than those in the genome-wide study (1.016 and 1.012). Furthermore, 585 
LD score regression on the genome-wide data shows that the majority of inflation is 586 
caused by polygenic risk (LD score intercept = 1.09 for both CD and UC, compared to 587 
λGC = 1.23 and 1.29). Together, these results show that our residual inflation is consistent 588 
with polygenic signal and modest residual confounding. We tested what effect correcting 589 
for the LD score intercept of 1.09 would have on posterior probabilities and credible sets 590 
and found no major differences compared to uncorrected values. The full comparison of λ 591 
values is shown in Extended Data Table 3c. 592 
Imputation 593 
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Imputation was performed separately in each Immunochip autosomal high-density region 594 
(185 total) from the 1000 Genomes Phase I integrated haplotype reference panel.  To 595 
prevent the edge effect, we extended each side of the high density regions by 50kbp.  596 
Two imputations were performed sequentially (Extended Data Figure 2) using software 597 
and parameters as described below.  The first imputation was performed immediately 598 
after the quality control, from which the major results were manually inspected (Manual 599 
cluster plot inspection, Methods).  The second imputation was performed after removing 600 
variants that failed the manual cluster plot inspection. We used SHAPEIT46,47 (versions: 601 
first imputation: v2.r644, second imputation: v2.r769) to pre-phase the genotypes, 602 
followed by IMPUTE213,14 (versions: first: 2.2.2, second: 2.3.0) to perform the 603 
imputation. The reference panels were downloaded from the IMPUTE2 website (first: 604 
Mar 2012 release, second: Dec 2013 release). After the second imputation, there were 605 
388,432 variants with good imputation quality (INFO > 0.4). These include 99.9% of 606 
variants with MAF ≥0.05, 99.3% of variants with 0.05>MAF ≥0.01, and 63.0% of 607 
variants with MAF < 0.01 (Extended Data Figure 6d-f), with similar success rates for 608 
both coding and non-coding variants, making it unlikely that missing variants 609 
substantially affect our fine-mapping conclusions.  610 
Manual cluster plot inspection  611 
Variants that had posterior probability greater than 50% or in credible sets mapped to ≤ 612 
10 variants were manually inspected using Evoker v2.248.  Each variant was inspected by 613 
three independent reviewers (ten reviewers participated) and scored as pass, fail or 614 
maybe.  Reviewers were blinded to the posterior probability of these variants. We 615 
removed variants that received one or more fails, or received less than 2 passes. 220 out 616 
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of 276 inspected variants passed this inspection, and 53 of 56 failed variants were 617 
restored by imputation.  There is no difference in MAF between the failed and the passed 618 
variants (P=0.66). A further cluster plot inspection flagged two additional failed variants 619 
after removing the failed variants from the first inspection and redoing the imputation and 620 
analysis. Dramatic clustering errors accounted for 27/58 flagged variants, which were 621 
eliminated from final credible sets. The remaining 31 had only minor issues, and the 622 
imputed data for these remained in our final credible sets, with marginally smaller 623 
posteriors (mean of the difference: 9.8%, P=0.06, paired t test). 624 
Establishing a P value threshold 625 
We used a multiple testing corrected P value threshold for associations of 1.35 x 10-6, 626 
which was established by permutation. We generated 200 permuted datasets by randomly 627 
shuffling phenotypes across samples and carried out association analyses for each 628 
permutation across all variants in high-density regions that overlap IBD-associated loci3.  629 
We stored (i) all the point-wise P values (𝛼"), as well as (ii) the “best” P values (𝛼#) of 630 
each of the 200 permuted datasets.  We then computed the empirical, experiment-wide P 631 
value (𝛼$)(corrected for multiple testing) for each of the tests as its rank/200 with respect 632 
to the 200 𝛼#.  We then estimated the number of independent tests performed in the 633 
studied regions, n, as the slope of the regression of log(1-𝛼$) on log(1-𝛼"), knowing that 634 𝛼$ = 1 − (1 − 𝛼")*, yielding a value of 37,056. The P value threshold was determined 635 
as 0.05/n ≈ 1.35 x 10-6. 636 
Detecting and fine-mapping association signals 637 
We used three fine-mapping methods (Supplementary Methods) to detect independent 638 
signals and create credible sets across 97 Immunochip autosomal high-density regions 639 
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that contained at least one variant with p < 1.35 x 10-6. Our process for merging the 640 
results of the three methods is described below and illustrated in Figure 1a. 641 
1. We merged signals from different methods if their credible sets overlapped. To 642 
ensure a conservative credible set, this new merged credible set included all variants 643 
from all merged signals (the union of constituent credible sets). We assigned each 644 
variant in the merged credible sets a posterior probability equal to the average of the 645 
probabilities from the methods that reported this signal. To filter out technical 646 
artifacts we required genotyped variants in small credible sets to pass manual cluster 647 
plot inspection (see above) and all imputed variants to have INFO > 0.4. For signals 648 
reported by only one or two methods that contain only imputed variants (i.e. no 649 
directly genotyped variants), we additionally required at least one variant with INFO > 650 
0.8 and MAF > 0.01.  651 
2. We next assigned each signal to a provisional combination of lead variant and 652 
phenotype (CD, UC or IBD) that maximized the marginal likelihood of equation 8 in 653 
Supplementary Methods. 654 
3. At loci with >1 signals, we built a multivariate model with all signals reported by all 655 
three methods, and tested all possible combinations of adding signals reported by one 656 
or two methods, as long as they still had p < 1.35 x 10-6 when jointly fitted in the 657 
multi-signal model. We selected the combination with the highest joint marginal 658 
likelihood (equation 8 in Supplementary Methods). 659 
Phenotype assignment of signals 660 
The provisional phenotype assignment carried out during the signal merging described 661 
above is merely a point estimate, and does not capture the uncertainty associated with the 662 
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phenotypic assignment. We therefore recomputed the assignment of each signal as CD-663 
specific, UC-specific or shared using the Bayesian multinomial model from fine-mapping 664 
method 2, Empirical covariance prior with Laplace approximation49, as it is designed to 665 
assess evidence of sharing in the presence of potentially correlated effect sizes. For the 666 
lead variant for each credible set, we calculated the marginal likelihoods as in equation 667 
13 from Supplementary Methods, restricting either βUC = 0 (for the CD-only model) or 668 
βCD = 0 (for the UC-only model), as well as using the unconstrained prior (for the 669 
associated-to-both model). We then calculated the log Bayes factor in favor of sharing, 670 
i.e. the log of the ratio of marginal likelihoods between the associated-to-both model and 671 
the best of the single-phenotype associated models. These sharing log Bayes factors are 672 
given in Supplementary Table 1 (column ‘sharingBF’), and are a probabilistic assessment 673 
of phenotype assignment: for instance, the log Bayes factor of 97.4 for the primary signal 674 
at IL23R suggests a very high certainty that this signal is shared across both CD and UC, 675 
whereas the log Bayes factor of 0.4 for the primary signal at FUT2 is more ambiguous. In 676 
addition to providing the log Bayes factor itself, we also applied a log Bayes factor cut-677 
off of 10 to select variants with strong evidence of being shared across phenotypes. 678 
Final filters 679 
These procedures generated some signals where all three methods largely agreed, and 680 
some where they differed. While the signals where the methods disagree are of interest 681 
for methods development, here we chose to focus on the most concordant signals, as they 682 
are most straightforward to interpret biologically. We therefore discarded all signals 683 
found by only one method (which completely removed one locus), and two loci where 684 
the ratio of marginal likelihoods (equation 8 in Supplementary Methods) for the best 685 
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model and the second-best model was < 10 (Supplementary Notes). After these filters 686 
(Extended Data Figure 7) we considered 139 signals from 94 regions (containing a total 687 
of 181,232 variants) to be confidently fine-mapped, and took them forward for 688 
subsequent analysis.  689 
Estimating the variance explained by the fine-mapping 690 
We used a mixed model framework to estimate the total risk variance attributable to the 691 
IBD risk loci, and to the signals identified in the fine-mapping. We used the GCTA 692 
software package50 to compute a gametic relationship matrix (G-matrix) using genotype 693 
dosage information for the genotyped variants in the high-density regions (which we will 694 
call 𝐆-.). We then fit a variety of variance component models by restricted maximum 695 
likelihood analysis using an underlying liability threshold model implemented with the 696 
DMU package51. The first model is a standard heritability mixed-model that includes 697 
fixed effects for five principal components (to correct for stratification) and a random 698 
effect summarizing the contribution of all variants in the fine-mapping regions, such that 699 
the liabilities across all individuals are distributed according to  700 𝑳 ∼ 𝑵 𝛽3𝑃𝐶3 + ⋯+ 𝛽8𝑃𝐶8, 	𝜆3𝐆-. + 1 −	𝜆3 𝐼	 , 701 
where 	𝜆3 is thus the variance explained by all variants in fine-mapping regions, which 702 
we estimate. We then fitted a model that included an additional random effect for the 703 
contribution of the lead variants that have been specifically identified (with G-matrix 704 𝐆"=>*?@A), such that the liability is distributed as 705 𝑳 ∼ 𝑵(𝛽3𝑃𝐶3 + ⋯+ 𝛽8𝑃𝐶8, 	𝜆′3𝐆-. + 	𝜆C𝐆"=>*?@A +	 1 −	𝜆′3	– 𝜆C 𝐼	). 706 
The variance explained by the signals under consideration is then given by the reduction 707 
in the variance explained by all variants in the fine-mapping regions between the two 708 
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models (	𝜆3 − 	𝜆′3). We used this approach to estimate what fraction of this variance was 709 
accounted for by (i) the single strongest signals in each region (as would be typically 710 
done prior to fine-mapping), or (ii) all signals identified in fine-mapping. We used Cox 711 
and Snell’s method52 to estimate the variance explained across individual signals 712 
(Extended Data Figure 3b) for computational efficiency.  713 
Overlap between transcription factor binding motifs and causal variants 714 
For each motif in the ENCODE TF ChIP-seq data (http://compbio.mit.edu/encode-715 
motifs/, accessed Nov 2014)20, we calculated the overall information content (IC) as the 716 
sum of IC for each position53, and only considered motifs with overall IC ≥ 14 bits 717 
(equivalent to 7 perfectly conserved positions). For every variant in a high-density region 718 
we determined whether it creates or disrupts a motif at a high-information site (IC ≥ 1.8).  719 
Overlap between epigenetic signatures and causal variants 720 
For each combination of 120 tissues and three histone marks (H3K4me1, H3K4me3 and 721 
H3K27ac) from the Roadmap Epigenome Project we calculated an overlap score, equal 722 
to the sum of fine-mapping posterior probabilities for all variants in peaks of that histone 723 
mark in that tissue.  We generated a null distribution of this score for each tissue/mark by 724 
shifting chromatin marks randomly (between 0bp and 44.53Mbp, the length of all high-725 
density regions) and circularly (peaks at the end of the region shifted to the beginning of 726 
the region) over the high-density regions while keeping the same inter-peak distances.  727 
To summarize these correlated results across many cell and tissue types we defined a set 728 
of “core” H3K4me1 immune and H3K27ac gut peaks as sets of overlapping peaks in 729 
cells that showed the strongest enrichment.  Intersects were made using bedtools v2.24.0 730 
default settings54.  We selected 6 immune cell types for H3K4me1 and 3 gut cell types for 731 
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H3K27ac (Supplementary Table 2).  We also chose controls (Supplementary Table 2) 732 
from non-immune and non-gut cell types with similar density of peaks in the fine-733 
mapped regions as compared to immune/gut cell types to confirm the tissue-specificity of 734 
the overlap. We used the phenotype assignments (described above) in dissecting the 735 
enrichment for the CD and UC signals. Sixty-five CD and 21 UC signals that were 736 
mapped to ≤ 50 variants were used in this analysis.  737 
Published eQTL summary statistics  738 
We used eQTL summary statistics from three published studies: 739 
• Peripheral blood eQTLs from the GODOT study29 of 2,752 twins, reporting loci with 740 
MAF>0.5%. Imputation was performed using the 1000 genomes reference panel11.  741 
• Peripheral blood eQTLs from the Westra et al. study30 of 8,086 individuals, including 742 
variants with MAF>5%. Imputation was performed using the HapMap 2 CEU 743 
population reference panel55.  744 
• CD14+ monocyte eQTLs from Table S2 in Fairfax et al.31, comprised of 432 745 
European individuals, measured in a naïve state and after stimulation with interferon-746 
γ (for 2 or 24 hours) or lipopolysaccharide, reporting loci with MAF>4% and 747 
FDR<0.05.  Imputation was performed using the 1000 genomes reference panel10.  748 
Processing and quality control of new eQTL ULg dataset 749 
A detailed description of the ULg dataset is in preparation (Momozawa et al., in 750 
preparation).  Briefly, we collected venous blood and intestinal biopsies at three locations 751 
(ileum, transverse colon and rectum) from 350 healthy individuals of European descent, 752 
average age 54 (range 17-87), 56% female. SNPs were genotyped on Illumina Human 753 
OmniExpress v1.0 arrays interrogating 730,525 variants, and SNPs and individuals were 754 
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subject to standard QC procedures using call rate, Hardy-Weinberg equilibrium, MAF ≥ 755 
0.05, and consistency between declared and genotype-based sex as criteria.  We further 756 
imputed genotypes at ~7 million variants on the entire cohort using the Impute2 software 757 
package13 and the 1,000 Genomes Project as reference population (Phase 3 integrated 758 
variant set, released 12 Oct 2014) 11,14.  From the blood, we purified CD4+, CD8+, 759 
CD19+, CD14+ and CD15+ cells by positive selection, and platelets (CD45-negative) by 760 
negative selection. RNA from all leucocyte samples and intestinal biopsies was 761 
hybridized on Illumina Human HT-12 arrays v4.  After standard QC, raw fluorescent 762 
intensities were variance stabilized56 and quantile normalized57 using the lumi R 763 
package58, and were corrected for sex, age, smoking status, number of probes with 764 
expression level significantly above background as fixed effects and array number 765 
(sentrix id) as random effect.  For each probe with measureable expression (detection P 766 
value < 0.05 in >25% of samples) we tested for cis-eQTLs at all variants within a 500 767 
kbp window.  The nominal P value of the best SNP within a cis-window was Sidak-768 
corrected for the window-specific number of independent tests.  The number of 769 
independent test in each window was estimated exactly in the same manner as for the 770 
number of independent test for fine-mapping methods (Establishing a P value threshold, 771 
Methods).  We estimated false discovery rates (q-values) from the resulting P  values 772 
across all probes using the qvalue R package59.  480 cis-eQTL with FDR ≤ 0.10 for 773 
which the lead SNPs (i.e. the SNP yielding the best P value for the cis-eQTL) mapped 774 
within the 97 high-density regions (94 fine-mapped plus 3 unresolved) were retained for 775 
further analyses.  776 
Naïve colocalization using lead SNPs  777 
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We calculated the number of IBD credible sets that contain a lead eQTL variant in a 778 
particular tissue (“observed”).  This number is then compared to the background number 779 
of overlaps (“expected”): 780 1 − 1 − 𝑁=F3 GH=∈"  781 
where 𝑁= is the total number of variants in region 𝑖 in 1000 genomes with an allele 782 
frequency greater than a certain threshold (equal to the threshold used for the original 783 
eQTL study), 𝐶= is the number of these variants that lie in IBD credible sets, and 𝑆 is a set 784 
of regions that have at least one significant eQTL. We simulated 1,000 trials per region 785 
with binomial probability equal to the regional background overlap rate:	1 − 1 −786 𝑁=F3 GH. Empirical P values were estimated by comparing the observed number of 787 
overlaps with the simulated number of the overlaps. More specifically, P value is defined 788 
as the proportion of trails that have equal or more overlaps in the simulations than the 789 
observed.  790 
Frequentist colocalization using conditional P values 791 
We next used conditional association to test for evidence of colocalization, as described 792 
in Nica et al.25. This method compares the P value of association for the lead SNP of an 793 
eQTL before and after conditioning on the SNP with the highest posterior in the credible 794 
set, and measures the drop in –log(P). An empirical P value for this drop is then 795 
calculated by comparing it to the drop for all variants in the high-density region. Because 796 
this method requires full genotypes we could only apply it to the ULg dataset (MAF > 797 
5%).  An empirical P value ≤ 0.05 was considered as evidence that the corresponding 798 
credible set is colocalized with the corresponding cis-eQTL.  To evaluate whether our 799 
fine-mapping associations colocalized with cis-eQTL more often than expected by 800 
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chance we counted the number of credible sets affecting at least one cis-eQTL with 801 
P≤0.05, and compared how often this number was matched or exceeded by 1,000 sets of 802 
variants that were randomly selected yet distributed amongst the loci in accordance with 803 
the real credible sets. The number of variants per set is same as the number of credible 804 
sets in this eQTL analysis (MAF matched, size≤50), shown in Extended Data Table 2. 805 
Bayesian colocalization using Bayes factors 806 
Finally, we used the Bayesian colocalization methodology described by Giambartolomei 807 
et al.60, modified to use the credible sets and posteriors generated by our fine-mapping 808 
methods (similarly only applicable to the ULg full genotype data). The method takes as 809 
input a pair of IBD and eQTL signals, with corresponding credible sets 	𝑆L#.  and 	𝑆MNOP, 810 
and posteriors for each variant 𝑝=L#.	and 𝑝=MNOP	 (with 𝑝=R = 0	∀	𝑖	 ∉ 𝑆R).  Credible sets 811 
and posteriors were generated for eQTL signals using the Bayesian quantitative 812 
association mode in SNPTest (with default parameters), with credible sets in regions with 813 
multiple independent signals generated conditional on all other signals. Our method 814 
calculates a Bayes factor (BF) summarizing the evidence in favor of a colocalized model 815 
(i.e. a single underlying causal variant between the IBD and eQTL signals) compared to a 816 
non-colocalized model (where different causal variants are driving the two signals), given 817 
by the ratio of marginal likelihoods  818 𝐵𝐹 = P(GX@XY?@=ZM[)P(\X]	YX@XY?@=ZM[). 819 
The marginal likelihood for the colocalized model (i.e. hypothesis 𝐻_ in Giambartolomei 820 
et al.) is given by 821 
𝐿 𝐶𝑜𝑙𝑜𝑐𝑎𝑙𝑖𝑧𝑒𝑑 ∝ 	 1𝑁 𝑝=L#.𝑝=MNOP=	∈	"ijk⋃	"mnop  822 
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and the marginal likelihood for the model where the signals are not colocalized (i.e., 823 
hypothesis 𝐻q) is given by: 824 𝐿 𝑁𝑜𝑡	𝑐𝑜𝑙𝑜𝑐𝑎𝑙𝑖𝑧𝑒𝑑 ∝ 	 1𝑁C − 𝑁 𝑝=L#.𝑝sMNOP=,s	∈	"ijk⋂	"mnop,=	us  825 
In both cases, N is the total number of variants in the region. We only count towards N 826 
variants that have 𝑟C > 0.2 with either the lead eQTL variant or the lead IBD variant. 827 
To measure enrichment in colocalization BFs compared to the null, we carried out 828 
a permutation analysis. In this analysis, we randomly reassigned eQTL signals to new 829 
fine-mapping regions to generate a set of simulated null datasets. This is carried out using 830 
the following scheme on variants and credible sets with the same MAF cut-off as the 831 
eQTL dataset (ULg, MAF > 5%):  832 
1. Estimate the standarized effect size 𝛽> for each eQTL signal 𝑔, equal to standard 833 
deviation increase in gene expression for each dose of the minor allele. 834 
2. Randomly reassign each eQTL signal to a new fine-mapping region, and then select a 835 
new causal variant with a MAF within 1 percentage point of the lead variant from the 836 
real signal. If multiple such variants exist, select one at random. If no such variants 837 
exist, pick the variant with the closest MAF. 838 
3. Generate new simulated gene expression signals for each individual from 839 
Normal(𝛽>𝑥s, 1 − 𝛽>C2𝑓 1 − 𝑓 	)	 where 𝑥s is the individual’s minor allele dosage at 840 
the new causal variant and f is the minor allele frequency. 841 
4. Carry out fine-mapping and calculate colocalization BFs for each pair of (real) IBD 842 
signal and (simulated) eQTL signal. 843 
5. Repeat stages 2-4 1000 times for each tissue type 844 
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We can use these permuted BFs to calculate P values for each IBD credible set, given by 845 
the proportion of time the permuted BFs were as large or greater than the one observed in 846 
the real dataset. To generate a high-quality set of colocalized eQTL and IBD signals, we 847 
take all IBD signals that have the colocalization BF > 2, P < 0.01 and 𝑟C (with the eQTL 848 
variant) >0.8.  849 
Code availability 850 
Computer code used in this study is provided in the ‘Software availability’ sections in 851 
Supplementary Methods. 852 
Data availability 853 
The data that support the findings of this study are available from the international IBD 854 
Genetics Consortium but restrictions apply to the availability of these data, which were 855 
used under license for the current study, and so are not publicly available. Data are 856 
however available from the authors upon reasonable request and with permission of the 857 
international IBD Genetics Consortium. 858 
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Extended Data Figure 1. Power of the fine-mapping analysis. Power (y axis) to identify the 
causal variant in a correlated pair (strength of correlation shown by color) increases with the 
significance of the association (x axis), and therefore with sample size and effect size.  The 
vertical dashed line shows the genome-wide significance level.  To estimate the relationship 
between the strength of association and our ability to fine-map it, we assumed that the 
association has only two causal variant candidates, and we defined the signal as successfully 
fine-mapped if the ratio of Bayes factors between the true causal variant and the non-causal 
variant is greater than 10 (a 91% posterior, assuming equal priors for the two candidate variants).  
Using equation (8) in Supplementary Methods, we have logBF = log Pr 𝒀	 SNP1Pr 𝒀	 SNP2 ≈ log Pr 𝒀	 SNP1, 𝜃3∗	Pr 𝒀	 SNP2, 𝜃C∗  
in which 𝜃∗ is maximum likelihood estimate of the parameter values.  The log-likelihood ratio 
follows a chi-square distribution: logBF~ − 12 𝜒3C − 𝜒CC = −12 𝜆 1 − 𝑟C  
in which λ is the chi-square statistic of the lead variant and r is the correlation coefficient 
between the two variants.  Because of the additive property of the chi-square distribution, logBF 
follows a non-central chi-square distribution with 1 degree of freedom and non-centrality 
parameter 𝜆 1 − 𝑟C /2.  Therefore, the power can calculated as the probability that logBF > 
log(10), given by the cumulative distribution function of the non-central chi-squared distribution. 
 
Extended Data Figure 2. Procedures in the fine-mapping analysis. Details for each stage are 
described in Methods. The dashed line means the imputation was performed only once after the 
manual inspection (not iteratively). 
 
Extended Data Figure 3. Variance explained. Variance explained by secondary, tertiary, … 
variants as a fraction of the primary signal at each locus.  
 
Extended Data Figure 4. Functional annotations. a, Functional annotation for 45 variants 
having posterior probability > 50%. b, Functional annotation for 116 association signals that are 
fine-mapped to ≤ 50 variants. Annotations are defined in Methods. We additionally grouped 
eQTLs into “Immune/Blood” (CD4+, CD8+, CD19+, CD14+ CD15+, platelets) and “Gut” 
(ileum, transverse colon and rectum).  The eQTLs were generated from the ULg dataset using 
the “frequentist colocalization using conditional P values” approach (Methods).  
 
Extended Data Figure 5. Size of credible sets. Comparison of credible set sizes for primary 
signals using each of our fine-mapping methods (methods 1, 2 and 3), the combined approach (as 
adopted in final results) and the approach described in Maller et al.6 (y axis) and the R2 > 0.6 cut-
off (x axis).  Fine-mapping maps most signals to smaller numbers of variants. 
 
Extended Data Figure 6. Distributions of the allele frequency and the imputation quality. 
Panels a-c: distribution of the risk allele frequency for 45 variants having > 50% posterior 
probability plotted against (a) posterior probability, (b) significance of the association as –
log10(P), and (c) odds ratio of the association. Variants are color coded according to their 
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functions. Odds ratio for IBD associations was the larger of odds ratios for CD and UC. Panels 
d-f: distribution of imputation quality (INFO measure from the IMPUTE2 program) for variants 
having MAF ≥5% (d), between 5% and 1% (e) and <1% (f). 
 
Extended Data Figure 7. Merging and adjudicating signals across methods.  The number of 
signals for each method is shown in the brackets, and for each method a black bar indicates a 
signal with p < 1.35 x 10–6, and a grey bar a signal that does not reach that threshold. The colored 
bar shows the final status of each signal after merging and model selection (Methods). “Low 
info” corresponds to INFO < 0.8 (the threshold used for signals reported by 1 or 2 methods) and 
“rare and imputed” to MAF < 0.01 and no genotyped variants in the credible set, regardless of 
INFO (Methods). 
 
Extended Data Table 1. Study samples. Genotyped samples in each batch for healthy controls 
(Control), Crohn’s disease (CD) and ulcerative colitis (UC). Batches were grouped into cohorts 
for further analysis (Controlling for population structure, batch effects and other confounders, 
Methods).    
 
Extended Data Table 2. Colocalization with eQTL. The number of IBD credible sets that 
colocalize with eQTLs using the naïve, frequentist and Bayesian approaches.  Significant 
observations are boldfaced. ‘Number of credible sets’ reports the number of credible sets that 
have MAF above the cut-off. 
 
Extended Data Table 3. Genomic inflation. Genomic inflation factors and LD score regression 
intercept for Crohn’s disease (CD), ulcerative colitis (UC) and both (IBD). a, Genomic inflation 
factors using the first four, five and six principal components. The factors were calculated using 
2,853 background variants from the Immunochip. b, Genomic inflation factors for subsets of the 
data (using five principal components for the same 2,853 background variants). Balanced, 
imbalanced and down-sampled cohorts are defined in Methods. Numbers in brackets indicate the 
95% confidence interval for the inflation factors (only estimated for the down-sampled cohorts). 
c, LD score regression intercept and genomic inflation factors (λGC and λ1000) from the largest IBD 
meta-analyses with genome-wide data (CD:GWAS and UC:GWAS).  
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